<?xml version="1.0" encoding="UTF-8"?>
<p id="p0135">Many researchers suggest a trial of antiviral medications to help suppress viral replication, and both ritonavir and lopinavir are being studied in clinical trials (Shionogi, Toyama Chemical; Clinical trials, 2020). The use of these protease inhibitors was proven to be efficacious during the original SARS epidemic (
 <xref rid="b0095" ref-type="bibr">Chu et al., 2004</xref>). Remdesivir (Gilead Pharmaceuticals Inc, Foster City, CA) is an investigational drug that was considered as a treatment for Ebola but never approved by the U.S. Food and Drug Administration. Remdesivir is currently being tested in clinical trials for efficacy against COVID-19. Select cases have shown that remdesivir is capable of shortening the time until clinical improvement in patients with COVID-19 infection (
 <xref rid="b0180" ref-type="bibr">Grein et al., 2020</xref>).
</p>
